RenovaCare has joined forces with StemCell Systems GmbH, one of Germany’s leading firms in the field of technologies for regenerative medicine, to advance its CellMist™ System and SkinGun™ delivery device toward commercial release.
StemCell Systems invents and engineers biomedical devices for regenerative medicine. Based in Berlin, Germany, their engineering services are geared toward providing innovation and quality to their research and development clients and partners.
The company’s international partners include the Medical Faculty of the Berlin Universities, Germany; the University of Pittsburgh; AstraZeneca; and the Karolinska Institute, Sweden. They also participate in a European Commission-funded consortium engaged in extracorporeal liver support, that includes institutions in seven European countries, with efforts based on the company’s liver support bioreactors and perfusion devices.
RenovaCare, Inc. is developing first-of-their-kind technologies for the regeneration of human organs, using a patient’s own stem cells. Their flagship CellMist™ System and SkinGun™ delivery technology has been shown in early human clinical use to rapidly regenerate and naturally heal skin for burn victims.
The Regenerative Medicine sector is advancing rapidly, thanks to positive clinical results, strong investor interest, particularly the strong interest in the space by large pharmaceutical firms. Regenerative medicine companies have attracted $1.3 billion in outside investment in 2013, and there are 575 potential cell and gene therapies in the development. “This industry is ready for prime time,” states Geoff MacKay, chair of the Alliance for Regenerative Medicine, in his January 2014 briefing on the state of the industry in San Francisco.
“As an innovation company, we create value through the inspiration, dedication, and excellence of our team. Our product development staff has several decades of accumulated experience and in this time we have built considerable resources in our tools for R&D contracting, prototyping, and clinical study scale production,” remarked Frank Schubert, Chief Technology Officer for StemCell Systems. “We are uniquely positioned in our collaboration with RenovaCare to bring a completely novel medical device and treatment technique to market in the United States.”
RenovaCare’s Director of Business Development Drew Danielson expressed that the company is excited to collaborate with StemCell Systems. “Their accumulated expertise in designing and producing tools for regenerative medicine really accelerates our ability to exploit the scope of our product base. We believe our proprietary technologies for processing and grafting the body’s most regenerative skin stem cells could open the door to much more rapid and effective treatment for a wide range of wounds and conditions, improving quality of life and enabling severely injured patients to get back on their feet more quickly than possible with current treatments,” Danielson remarked.